Abstract: Technologies for power-aware scheduling include a computing device that receives network packets. The computing device classifies the network packets by priority level and then assigns each network packet to a performance group bin. The packets are assigned based on priority level and other performance criteria. The computing device schedules the network packets assigned to each performance group for processing by a processing engine such as a processor core. Network packets assigned to performance groups having a high priority level are scheduled for processing by processing engines with a high performance level. The computing device may select performance levels for processing engines based on processing workload of the network packets. The computing device may control the performance level of the processing engines, for example by controlling the frequency of processor cores. The processing workload may include packet encryption. Other embodiments are described and claimed.

Abstract: A radiotherapy device is disclosed. The radiotherapy device includes a radiation source, a detecting means and controller communicatively coupled to the radiation source and the detecting means. The radiation source is configured to generate a treatment beam for irradiating a subject. The detecting means is configured to detect a motion of the subject, the motion comprising a first physiological motion component and a second physiological motion component.

Abstract: Systems and methods for generating three-dimensional models with correlated three-dimensional and two dimensional imagery data are provided. In particular, imagery data can be captured in two dimensions and three dimensions. Imagery data can be transformed into models. Two-dimensional data and three-dimensional data can be correlated within models. Two-dimensional data can be selected for display within a three-dimensional model. Modifications can be made to the three-dimensional model and can be displayed within a three-dimensional model or within two-dimensional data. Models can transition between two dimensional imagery data and three dimensional imagery data.

Abstract: The present invention relates to methods of manufacture for producing a drug substance (DS) or drug product (DP) comprising a mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO: 36 and a light chain (LC) comprising SEQ ID NO: 37.

Abstract: A biopharmaceutical flow port, a biopharmaceutical liquid container assembly, and a method for manufacturing the biopharmaceutical flow port and the biopharmaceutical liquid container assembly are described. The biopharmaceutical flow port includes a hose barb coupled to an elliptic body. The hose barb includes a bore. The elliptic body includes a flow passage, a first edge, and a second edge. The flow passage is fluidly coupled to the bore. The first edge extends from the elliptic body away from the flow passage in a first direction and the second edge extends from the elliptic body away from the flow passage in a second direction opposite the first direction. The biopharmaceutical liquid container assembly includes a biopharmaceutical liquid container with an opening and the biopharmaceutical flow port coupled to the biopharmaceutical liquid container within the opening and in fluid communication with a volume of the biopharmaceutical liquid container.

Abstract: A set of tools for prying and removing virtually all vehicle trim and upholstery items includes a sharp curve trim removal tool having an elongate cylindrical rod with a scalloped, scoop-shaped distal end and a pocket clip, a defined fulcrum trim and upholstery removal tool having a flat bar having a rectilinear handle segment extending from the tool proximal end to a middle segment, and a curved tool distal end defining a rounded corner functioning as an acute upturned fulcrum curve along a tool lower surface, giving the user added mechanical advantage. The bar tapers to a sharp edge at the distal end. The set further includes a clip removal tool which is the same as the trim and upholstery removal tool except that it additionally includes a central notch in the sharp edge at the distal end for clip engagement.

Abstract: An accelerator device may access an input data chunk to be compressed by the accelerator device. The accelerator device may access an entropy value for the input data chunk. The accelerator device may compress the input data chunk or return an indication that the input data chunk will not be compressed based on the entropy value and an entropy threshold.

Abstract: Technologies for performance monitoring include a computing device having multiple processor cores. The computing device performs a training workload with a processor core by continuously polling an empty input queue. The computing device determines empty polling thresholds based on the empty polling workload. The computing device performs a packet processing workload with one or more processor cores by continuously polling input queues associated with network traffic. The computing device compares a measured number of empty polls performed by the packet processing workload against the empty polling thresholds. The computing device configures power management of one or more processor cores in response to the comparison. The computing device may determine empty polling trends and compare the measured number of empty polls and the empty polling trends to the empty polling thresholds. Other embodiments are described and claimed.

Abstract: An accelerator device determines a compression format based on a header of a structured data element to be decompressed. The accelerator device may configure the accelerator device based on the compression format. The accelerator device may decompress a data block of the structured data element based on the configuration.

Abstract: Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

Abstract: Continuous processes for the manufacture of porous carbon materials are disclosed. The process includes the reaction of a self-assembling polymeric mixture, followed by drying and extrusion of the cured, semi-dry polymeric gel extrudate prior to pyrolysis. Also disclosed are porous carbon materials, such as porous carbon monoliths, produced by these processes. In particular, hierarchically porous carbon materials for use as a catalyst support or for the adsorption of gas and other substances that are manufactured by these processes are also disclosed.

Abstract: The present invention relates to a breath tester. The breath tester includes a sensor for sensing a mind-altering substance in breath from a blower (i.e., person blowing and providing a sample). A breath guide is provided for guiding the breath so that it is not returned to the blower. Advantageously, the guide guides the breath so that it is not returned to the blower to thereby minimise the likelihood of spread of infectious disease.

Abstract: A peptide that binds to elongation initiation factor 4E (eIF4E) comprising the amino acid sequence CEX1GX2X3X4X5C (SEQ ID NO: 1), where X1 is an amino acid selected from the group consisting of threonine (T), methionine (M) or leucine (L), X2 and X3 is an amino acid selected from the group consisting of phenylalanine (F), modified phenylalanine and tyrosine (Y), X4 and X5 is any amino acid, wherein the two cysteine residues are joined by a disulphide bond. Further, pharmaceutical compositions and uses of the peptide, and pharmaceutical compositions are provided.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.

Abstract: Technologies for performance monitoring include a computing device having multiple processor cores. The computing device performs a training workload with a processor core by continuously polling an empty input queue. The computing device determines empty polling thresholds based on the empty polling workload. The computing device performs a packet processing workload with one or more processor cores by continuously polling input queues associated with network traffic. The computing device compares a measured number of empty polls performed by the packet processing workload against the empty polling thresholds. The computing device configures power management of one or more processor cores in response to the comparison. The computing device may determine empty polling trends and compare the measured number of empty polls and the empty polling trends to the empty polling thresholds. Other embodiments are described and claimed.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1 to R3, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing one or more diseases or disorders associated with integrated stress response.

Abstract: An ophthalmic and associated methods are disclosed. In one example a plurality of ophthalmic tools are located on a single cart for collecting ophthalmic data. Data may be recorded in a standardized format to aid in comparison between records in a database. In one example the standardized format facilitates fast and more accurate diagnoses of ophthalmic conditions.

Abstract: Computer-implemented methods and systems for performing a local assembly of a genomic region of interest include the de novo or assisted creation of a directed graph, such as a directed acyclic graph (DAG), from a plurality of obtained nucleotide sequence reads. First and second sequence reads are aligned to each other to define at least one node of the DAG. Successive alignments of the remaining sequence reads to the then-defined DAG are performed to extend nodes and/or add nodes to the DAG. Graph-aware alignment techniques that produce alignment scores or indicators are employed in defining the nodes of the DAG from the sequence reads. The created DAG represents and describes in detail the genomic region of interest and can be used to perform variant calls.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: The present invention relates to non-membrane disruptive and p53 activating stapled peptides, as well as methods of treatment of cancer involving the use of these peptides. In one embodiment, the peptide comprises or consist of the amino acid sequence of TSFXaa1EY-WXaa3LLXaa2, where Xaa1 is (R)-2-(7?-octenyl)alanine or derivative thereof, or is (R)-2-(4?-pentenyl)alanine or derivative thereof; and Xaa2 and Xaa3 are independently any type of amino acid or modified amino acid. In another embodiment, the peptide comprising or consisting of the amino acid sequence of TSFXaa1EYW Xaa3LLXaa2ENXaa5, wherein Xaa1 and Xaa3 are any type of amino acid or modified amino acid; Xaa2 is S, or P, or (S)-2-(4?-pentenyl)alanine or a derivative of (S)-2-(4?-pentenyl)alanine; and wherein Xaa5 is F or Y.